Holen Sie sich die Stockscreener-App
19.16
1.29%
-0.29
Schlusskurs vom Vortag:
$19.45
Offen:
$19.79
24-Stunden-Volumen:
9,913
Relative Volume:
0.26
Marktkapitalisierung:
$918.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.28M
KGV:
-9.6006
EPS:
-1.9957
Netto-Cashflow:
$-57.45M
1W Leistung:
+1.00%
1M Leistung:
+1.75%
6M Leistung:
+25.57%
1J Leistung:
+63.27%
1-Tages-Spanne:
$19.14
$19.79
1-Wochen-Bereich:
$19.13
$20.45
52-Wochen-Spanne:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
19.14 | 1.04B | 0 | -75.28M | -57.45M | -1.9957 |
|
ONC
Beone Medicines Ltd Adr
|
245.06 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.65 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.40 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.11 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
501.32 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Trend Tracker for (OCS) - news.stocktradersdaily.com
Trend Tracker for (OCSAW) - news.stocktradersdaily.com
HC Wainwright Estimates Oculis’ Q2 Earnings (NASDAQ:OCS) - Defense World
HC Wainwright Weighs in on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume Increase on Analyst Upgrade - Defense World
Oculis (NASDAQ:OCS) Price Target Raised to $33.00 - Defense World
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Oculis Announces 2025 Annual General Meeting Details - TipRanks
Oculis Publishes Invitation to the Annual General Meeting - The Manila Times
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Oculis Reports Q1 2025 Financial Results and Provides Company Update - The Manila Times
Oculis Holding AG Reports Strong Q1 Progress - TipRanks
Learn to Evaluate (OCSAW) using the Charts - news.stocktradersdaily.com
Earnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to Decline - MSN
Oculis Holding AG reports results for the quarter ended March 31Earnings Summary - TradingView
Oculis Holding AG Reports Q1 2025 Financial Results - TipRanks
Oculis to Present at Upcoming May Investor Conferences - EIN News
REG-Oculis to Present at Upcoming May Investor Conferences - TradingView
Long Term Trading Analysis for (OCS) - news.stocktradersdaily.com
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - The Manila Times
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in 2025 - Nasdaq
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewswire Inc.
Oculis Holding AG to Present Innovative Late-Stage Pipeline at Major Ophthalmology Conferences in May 2025 - Nasdaq
Oculis Updates Share Capital - The Manila Times
Long Term Trading Analysis for (OCSAW) - news.stocktradersdaily.com
(OCS) Trading Advice - news.stocktradersdaily.com
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Increases Oculis (NASDAQ:OCS) Price Target to $32.00 - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up Following Analyst Upgrade - Defense World
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - The Manila Times
Stifel maintains Buy rating, $35 target on Oculis shares By Investing.com - Investing.com South Africa
Stifel maintains Buy rating, $35 target on Oculis shares - Investing.com
Oculis Holding AG Unveils Key Clinical Updates and Future Outlook at R&D Day - TipRanks
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - The Manila Times
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis Completes Enrollment in Late-Stage Diabetic Macular Edema Trials - marketscreener.com
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
REG-Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - TradingView
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - The Manila Times
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):